Tools
Politician · U.S. House

Julie Johnson

U.S. House of Representatives · Democrat · STOCK Act disclosures, as of Nov 16, 2026
Purchases
0
reported transactions
Sales
3
reported transactions
Stocks traded
3
distinct tickers
PTR filings
4
in the current window

Copycat portfolio · 2021–2026

If a paper portfolio had bought one equal-weight unit of every stock purchase this member disclosed — at the first close after each filing became public — and sold a name only when a sale was disclosed, it would stand at +46.4% cumulatively to Sep 30, 2026, against +27.5% for SPY over the same span (+18.9% excess). 110 disclosed buys scored, 70 positions closed (79% of them profitable), 40 still open at period end. Full scoreboard and rules: Track Record · Methodology.

About Julie Johnson

Julie Johnson is a Democrat representing Texas's 32nd Congressional District in the U.S. House of Representatives, covering parts of the Dallas area. An attorney by profession, she previously served in the Texas House of Representatives before winning her U.S. House seat in the 2024 election and taking office in January 2025. She is in her first term in Congress, and her background in state government and the law shapes the legislative work she does for a district that spans densely populated suburbs north and east of Dallas.

In the 2026 window shown on this page, Johnson reported three sales and no purchases, across three stocks. She sold Abbott Laboratories and Accenture, both on May 12, 2026, and Warner Bros. Discovery on October 7, 2026, with each sale in the $1,001 to $15,000 range. The page draws on four periodic transaction reports filed with the U.S. House Clerk. The pattern is a small set of exits from health care, consulting, and media holdings, with nothing bought to replace them in the same window.

The page's copycat portfolio, which scores every disclosed purchase from 2021 through 2026 by buying one equal-weight unit at the first close after each filing became public, stands at +46.4% cumulatively to September 30, 2026, against +27.5% for SPY over the same span, an excess return of +18.9 percentage points. It scored 110 disclosed buys, of which 70 positions were closed, 79% of them profitably, with 40 positions still open at the end of the period. That is one of the stronger copycat records among the members on this site, even though the current window itself shows only sales.

Reported trades by stock

TickerCompanyBuysSellsLatest tradeReported amount ranges
ABTABBOTT LABORATORIES01May 12, 2026$1,001 - $15,000
ACNAccenture plc01May 12, 2026$1,001 - $15,000
WBDWarner Bros. Discovery, Inc.01Oct 7, 2026$1,001 - $15,000

STOCK Act reports disclose amount ranges, not exact values. Reports can be filed up to 45 days after the trade date.

Source filings

· Periodic Transaction Report (PDF) — filed Jan 15, 2026, DocID 20033789

· Periodic Transaction Report (PDF) — filed Nov 10, 2026, DocID 20035806

· Periodic Transaction Report (PDF) — filed Jun 12, 2026, DocID 20034706

· Periodic Transaction Report (PDF) — filed Aug 5, 2026, DocID 20035035

Source: U.S. House Clerk financial disclosures (disclosures-clerk.house.gov). Window: U.S. House PTR filings for 2026; transactions dated on or after 2026-04-01. Scanned-image PTRs that cannot be machine-read are excluded, never estimated.

Counting rule: rows with the same account, same date and same amount range count as one trade.

Why copying this is harder than it looks

STOCK Act reports arrive up to 45 days after the trade, so trades shown here may be weeks old. Reports disclose amount ranges, not exact values. Copying the list also means copying its timing and prices.

Read the original reports at U.S. House Clerk financial disclosures.

Not investment advice. Filings are delayed and incomplete.

How we measure: Methodology · Track Record · All members.

Related

Politicians · Track Record: how Congress portfolios scored · Practice timing

One email a week: the week’s new filings and research. Subscribe free

← Josh Gottheimer  ·  Kelly Louise Morrison →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.